Informa Pharma Intelligence
AWARDS
JAPAN

LICENSING DEAL OF THE YEAR

Deals considered here are those that involve the licensing of a particular drug, project or group of drugs/projects from one company to another for further development and/ or marketing. (It does not include more involved partnerships between companies to explore particular therapeutic strategies.)

The judges will look at all aspects from monetary and strategic value to the benefits they give to both sides. To qualify, licensing deals must have been closed during calendar year 2021.

Please complete the contact and entry sections and email to Natalia Kay
Senior Events Manager
E: Natalia.Kay@informa.com

To enter this category, please answer the following:

- Outline the structure of the deal, giving the names of the parties involved, the drug candidate(s) concerned, and what rights it covers.
- Monetary value of the deal in up-front and milestone payments.
- Geographic spread of the deal and does it allow any party to enter new markets?
- Strategic value of the licensed product to the licensee's business.
- Please explain how the licensed product was the best possible candidate to complement the rest of the licensee's pipeline or particular disease franchise.

Details of person submitting the entry:

Entering Company

Name of the person submitting this entry forms

Organization of the person submitting this entry form (if different from 'Entering Company')

Email address

Twitter handle of the entering company

Website of the entering company

**References**
Include any links to online references that may support your entry

Entry summary: (approx. 250 words)

Please enter a summary of your entry, this may be used in Awards publicity material so please do not include any confidential information.

Entry: (approx. 1500 words)

Please use this box to submit your entry, referring to the questions in the category criteria.